Variations and progress in worksharing EMA/ IFAH-Europe Info Day 14 March 2014 Presented by: Melanie Leivers Head of Veterinary Regulatory and Organisational Support An agency of the European Union
Variations and progress in worksharing The aim of this presentation is to: • focus on w orksharing ( w hat it is, types of worksharing requests, num ber of applications and areas for im provem ent ) • highlight certain variations and how the EMA w orks to reduce adm inistrative burden where possible (classifications, inclusion of Croatian translations etc.) 1 Variations and progress in worksharing
Progress in worksharing W hat is w orksharing? Legal base is Article 20 of Commission Regulation 1234/ 2008: “… … .where a minor variation of type IB, a major variation of type II or a group of variations in the cases of point (b) of Article 7(2) which does not contain any extension relates to several marketing authorisations owned by the same holder, the holder of such authorisations may follow the procedure laid down in paragraphs 3 to 9 of this Article.” 2 Variations and progress in worksharing
Progress in worksharing Different reference authorities depending on w hich types of product are included in the application - • EMA as reference authority; • Two or more Centrally Authorised Products (CAPs) (CAP-only WS) • One or more CAPs + nationally authorised products (NAPs)/ MRP/ DCP (CAP-NAP WS) • National competent authority as reference authority; • More than one NAP/ MRP/ DCP N.B. EMA must be reference authority where a CAP involved 3 Variations and progress in worksharing
Progress in worksharing • One integrated submission package • For work-sharing involving CAPs the outcome is a CVMP opinion (and sometimes a Commission Decision) – national follow-up required for NAPs involved in CAP/ NAP worksharing • A m ixed outcom e (where a group of variations has been submitted for work-sharing) is possible i.e. some positive and some negative • Aim is to avoid duplication of work 4 Variations and progress in worksharing
Progress in worksharing Workshared applications can include many different products but must always comply with: • Same change or same group of changes to each product • No product-specific assessment necessary • Same marketing authorisation holder Timetable – 60 days (90 days for e.g. non-food target species) 5 Variations and progress in worksharing
Progress in worksharing Types of EMA worksharing requests • Requests include not only Type IB and Type II variations but also “IG” applications and large groups of variations • IGs are IA variations which are “work-shared” between CAPs – the worksharing procedure does not apply to Type IA/ IA IN variations but under Article 7(2) of the Regulation where the same Type IA is to be submitted for a number of products to the same relevant authority a single notification may cover all such variations • In addition, it is also possible to group Type IA or IA IN variations with a Type IB or Type II variation being submitted for a worksharing procedure. In such case, the review of the Type IA or IA IN variation will be performed as part of the worksharing procedure 6 Variations and progress in worksharing
Progress in worksharing Types of EMA worksharing requests • Mostly quality/ m anufacturer changes • I Gs are frequently quality and DDPS/ QPPV related 7 Variations and progress in worksharing
Progress in worksharing Num ber of applications : EMA gaining in experience - Since 1 January 2010 22 WS applications (includes groups) (includes 6 CAP/ NAP WS) “IG” requests (IAs) 23 IG applications 8 Variations and progress in worksharing
Progress in worksharing Areas for im provem ent in the process : • Some disappointment expressed initially by applicants that EMA was not able to accept informal workshared applications whereas CMDv could; • Future amendment to guidance – needs to be less restrictive and allow Type IAs across procedures e.g. Detailed Description of the Pharmacovigilance System (DDPS) across all authorisations? 9 Variations and progress in worksharing
Progress in worksharing Areas for im provem ent in the process : • Centrally authorised products – may need an amendment to the Commission Decision – this increases the time to approval; • Commission Decisions amend/ update product annexes per product so product information changes for each product may be needed; • Working to streamline communication between NCAs and EMA during worksharing procedures where EMA is reference authority 10 Variations and progress in worksharing
Progress in worksharing Areas for im provem ent in the process : • Worksharing is welcomed but comments received indicate that the procedure is too long for minor changes! • Type IB workshares to be done as Type IBs? i.e. 30 days and not 60 days? • Aim was to reduce the administrative burden 11 Variations and progress in worksharing
Variations • Procedural and Classification guidance was updated in 2013 • Some classification changes occurred – mainly due to human pharmacovigilance legislation • The following examples – there may be others! – are particular variations which need to be highlighted 12 Variations and progress in worksharing
Variations A.8 - comes about due to Falsified Medicines legislation (human only) – not applicable to VMPs 13 Variations and progress in worksharing
Variations C.I .3 - changes in the SPC further to PSUR: current wording means it is no longer applicable to veterinary medicines CAPs - C.I.4 z (MRP/ DCP – C.1.3 z) – both Type IB by default (reflects previous guidance) 14 Variations and progress in worksharing
Variations Safety, Efficacy, PhV Variations: Pharm acovigilance System If you have used the previous classification guidance take care here! The principles are the same BUT num bering has changed : Type IA: Changes to an existing PhV system ( C.I .9 ) Type IB: New PhV system previously assessed for another product of same MAH ( C.I I .7 ) Type II: New PhV system not previously assessed for another product of same MAH ( C.I I .7 ) 15 Variations and progress in worksharing
Variations Incorporating Croatian translations into CAP annexes Guidance on the website but possibilities more limited for veterinary medicines – no Article 61(3): • Include the Croatian translations in any on-going procedure affecting the Annexes or • Incorporate the Croatian language versions in the 1 2 -m onthly update procedure (i.e. without a variation) or • Use a C.I I .6 ( I A) variation procedure in order to effect the change (which is effective immediately after the EMA notification, even if not appearing on the Commission’s website) 16 Variations and progress in worksharing
Variations • EMA aims to be pragmatic but also needs to stay within the requirements; • Where possible Type IB by default classification is used • Any queries for centrally authorised products? ---- 17 Variations and progress in worksharing
Vet applications team Please send email to vet.applications@ema.europa.eu and the team will be happy to help you! Wendy Parker ( on leave ) Anne-Christine Lantin Urszula Piotrowska Dorota Kaczmarczyk Tunde Horinka 18 Variations and progress in worksharing
Thank you for your attention! 19 Variations and progress in worksharing
Recommend
More recommend
